This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Remuzzi, A. Articles by Remuzzi, G. Search for Related Content PubMed PubMed Citation Articles by Remuzzi, A. Articles by Remuzzi, G. Social Bookmarking                         What's this?

Review: Potential protective effects of telmisartan on renal function deterioration

Mario Negri Institute for Pharmacological Research, Via Gavazzeni, 11 24125 Bergamo, Italy, aremuzzi{at}marionegri.it

Giuseppe Remuzzi

Mario Negri Institute for Pharmacological Research, Via Gavazzeni, 11 24125 Bergamo, Italy, Unit of Nephrology and Dialysis, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Largo Barozzi, 1 24128 Bergamo, Italy

Experimental and clinical evidence is now available that antagonism of angiotensin II (Ang II) with both angiotensin-converting enzyme inhibitors and Ang II receptor antagonists (AIIAs) is effective in slowing the rate of renal functional loss in patients affected by proteinuric kidney diseases.Among AIIAs, telmisartan has been shown to be characterised by a potent and long lasting antihypertensive effect that may be associated with another specific effect of this molecule, the partial agonism of the peroxisome-activated receptor-gamma.Although this action has also been observed with other AIIAs, telmisartan seems to exert a more effective and specific action as in such a way to influence beneficially adipocyte metabolism, diabetes onset and insulin resistance. Recently, we have demonstrated, at the experimental and clinical level, that sustained blockade of Ang II biological activity with this class of compounds can potentially reduce the progression of renal dysfunction and in some circumstances induce the regression of renal functional and structural changes. In this review we analyse available experimental and clinical data that suggest that blocking Ang II with telmisartan may effectively ameliorate renal dysfunction in patients affected by the now frequently observed condition termed metabolic syndrome.

Key Words: angiotensin II peroxisome-activated receptor-gamma • angiotensin receptor antagonists • angiotensin-converting enzyme inhibitors • metabolic syndrome • insulin resistance renal diseases • renoprotection

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 4, 185-191 (2006)
DOI: 10.3317/jraas.2006.036


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?